Aduro Biotech to Host Conference Call
October 23 2016 - 04:00PM
Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that it will hold
a conference call to provide a corporate update tomorrow, October
24, 2016, at 6:00 a.m. PT. To participate in the conference call,
please dial (844) 309-0604 (domestic) or (574) 990-9932
(international) and refer to conference ID 4915023. Live audio of
the conference call will be simultaneously webcast and will be
available to members of the news media, investors and the general
public at http://edge.media-server.com/m/p/rk79zbwm and under the
Investors section of the company’s website at investors.aduro.com.
The webcast will be archived and available for replay for at
least one month after the event.
About Aduro Aduro Biotech, Inc.
is an immunotherapy company focused on the discovery, development
and commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
pancreatic, ovarian, lung and prostate cancers, mesothelioma and
glioblastoma. Aduro's STING Pathway Activator platform is designed
to activate the intracellular STING receptor, resulting in a potent
tumor-specific immune response. ADU-S100 is the first STING Pathway
Activator compound to enter the clinic and is currently being
evaluated in a Phase 1 study in patients with cutaneously
accessible metastatic solid tumors or lymphomas. Aduro’s B-select
monoclonal antibody platform includes a number of immune modulating
assets in research and preclinical development. Aduro is
collaborating with leading global pharmaceutical companies to
expand its products and technology platforms. For more information,
please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements
regarding our intentions or current expectations concerning, among
other things, the potential for our technology platforms, plans,
and the potential for eventual regulatory approval of our product
candidates. In some cases, you can identify these statements by
forward-looking words such as “may,” “will,” “continue,”
“anticipate,” “intend,” “could,” “project,” “expect” or the
negative or plural of these words or similar expressions.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results and events to differ materially from those anticipated,
including, but not limited to, our history of net operating losses
and uncertainty regarding our ability to achieve profitability, our
ability to develop and commercialize our product candidates, our
ability to use and expand our technology platforms to build a
pipeline of product candidates, our ability to obtain and maintain
regulatory approval of our product candidates, our inability to
operate in a competitive industry and compete successfully against
competitors that have greater resources than we do, our reliance on
third parties, and our ability to obtain and adequately protect
intellectual property rights for our product candidates. We
discuss many of these risks in greater detail under the heading
“Risk Factors” contained in our quarterly report on Form 10-Q for
the quarter ended June 30, 2016, which is on file with the
Securities and Exchange Commission. Any forward-looking statements
that we make in this press release speak only as of the date of
this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:
Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264
Media Contact:
Angela Bitting
925 202 6211
press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2023 to Mar 2024